The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
c-Myc Proteolysis by the Ubiquitin-Proteasome Pathway: Stabilization of c-Myc in Burkitt's Lymphoma Cells
Open accessAbstract
The c-Myc oncoprotein is a transcription factor which is a critical regulator of cellular proliferation. Deregulated expression of c-Myc is associated with many human cancers, including Burkitt's lymphoma. The c-Myc protein is normally degraded very rapidly with a half-life of 20 to 30 min. Here we demonstrate that proteolysis of c-Myc in vivo is mediated by the ubiquitin-proteasome pathway. Inhibition of proteasome activity blocks c-Myc degradation, and c-Myc is a substrate for ubiquitination in vivo. Furthermore, an increase in c-Myc stability occurs in mitotic cells and is associated with inhibited c-Myc ubiquitination. Deletion analysis was used to identify regions of the c-Myc protein which are required for rapid proteolysis. We found that a centrally located PEST sequence, amino acids 226 to 270, is necessary for rapid c-Myc degradation, but not for ubiquitination. Also, N-terminal sequences, located within the first 158 amino acids of c-Myc, are necessary for both efficient c-Myc ubiquitination and subsequent degradation. We found that c-Myc is significantly stabilized (two- to sixfold) in many Burkitt's lymphoma-derived cell lines, suggesting that aberrant c-Myc proteolysis may play a role in the pathogenesis of Burkitt's lymphoma. Finally, mutation of Thr-58, a major phosphorylation site in c-Myc and a mutational hot spot in Burkitt's lymphoma, increases c-Myc stability; however, mutation of c-Myc is not essential for stabilization in Burkitt's lymphoma cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapid and efficient site-specific mutagenesis without phenotypic selection.
Kunkel, T. A. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.2.488 · Cited by 7,206
Induction of apoptosis in fibroblasts by c-myc protein
Evan, G. I., Wyllie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H., Brooks, M., Waters, C. M., Penn, L. Z., & Hancock, D. C. (1992) · Cell · doi:10.1016/0092-8674(92)90123-t · Cited by 2,935
Amino Acid Sequences Common to Rapidly Degraded Proteins: The PEST Hypothesis
Rogers, S., Wells, R., & Rechsteiner, M. (1986) · Science · doi:10.1126/science.2876518 · Cited by 2,537
Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., & Goldberg, A. L. (1994) · Cell · doi:10.1016/s0092-8674(94)90462-6 · Cited by 2,524
The ubiquitin-proteasome proteolytic pathway
Ciechanover, A. (1994) · Cell · doi:10.1016/0092-8674(94)90396-4 · Cited by 1,791
PEST sequences and regulation by proteolysis
Rechsteiner, M., & Rogers, S. W. (1996) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(96)10031-1 · Cited by 1,640
Fenteany, G., Standaert, R. F., Lane, W. S., Choi, S., Corey, E. J., & Schreiber, S. L. (1995) · Science · doi:10.1126/science.7732382 · Cited by 1,583
The ubiquitin-proteasome pathway: on protein death and cell life
Ciechanover, A. (1998) · The EMBO Journal · doi:10.1093/emboj/17.24.7151 · Cited by 1,426
Barrett, A. J., Kembhavi, A. A., Brown, M. A., Kirschke, H., Knight, C. G., Tamai, M., & Hanada, K. (1982) · Biochemical Journal · doi:10.1042/bj2010189 · Cited by 1,026
Ubiquitin-dependent c-Jun degradation in vivo is mediated by the δ domain
Treier, M., Staszewski, L. M., & Bohmann, D. (1994) · Cell · doi:10.1016/s0092-8674(94)90502-9 · Cited by 923
Cited by
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
Targeting G-quadruplexes in gene promoters: a novel anticancer strategy?
Balasubramanian, S., Hurley, L. H., & Neidle, S. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3428 · Cited by 1,692
Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability
Sears, R., Nuckolls, F., Haura, E., Taya, Y., Tamai, K., & Nevins, J. R. (2000) · Genes & Development · doi:10.1101/gad.836800 · Cited by 1,393
c-MYC: more than just a matter of life and death
Pelengaris, S., Khan, M., & Evan, G. (2002) · Nature Reviews Cancer · doi:10.1038/nrc904 · Cited by 1,178
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Obeng, E. A., Carlson, L. M., Gutman, D. M., Harrington, W. J., Lee, K. P., & Boise, L. H. (2006) · Blood · doi:10.1182/blood-2005-08-3531 · Cited by 1,143
Welcker, M., & Clurman, B. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2290 · Cited by 1,084
Welcker, M., Orian, A., Jin, J., Grim, J. A., Harper, J. W., Eisenman, R. N., & Clurman, B. E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402770101 · Cited by 941
Phosphorylation‐dependent degradation of c‐Myc is mediated by the F‐box protein Fbw7
Yada, M., Hatakeyama, S., Kamura, T., Nishiyama, M., Tsunematsu, R., Imaki, H., Ishida, N., Okumura, F., Nakayama, K., & Nakayama, K. I. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600217 · Cited by 808
Yeh, E., Cunningham, M., Arnold, H., Chasse, D., Monteith, T., Ivaldi, G., Hahn, W. C., Stukenberg, P. T., Shenolikar, S., Uchida, T., et al. (2004) · Nature Cell Biology · doi:10.1038/ncb1110 · Cited by 791
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T. A., Treon, S. P., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202445099 · Cited by 741
Chang, F., Steelman, L. S., Lee, J. T., Shelton, J. G., Navolanic, P. M., Blalock, W. L., Franklin, R. A., & McCubrey, J. A. (2003) · Leukemia · doi:10.1038/sj.leu.2402945 · Cited by 725
Intrinsic Disorder and Functional Proteomics
Radivojac, P., Iakoucheva, L. M., Oldfield, C. J., Obradovic, Z., Uversky, V. N., & Dunker, A. K. (2007) · Biophysical Journal · doi:10.1529/biophysj.106.094045 · Cited by 706
Mechanisms and function of substrate recruitment by F-box proteins
Skaar, J. R., Pagan, J. K., & Pagano, M. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3582 · Cited by 689
Adult Burkitt leukemia and lymphoma
Blum, K. A., Lozanski, G., & Byrd, J. C. (2004) · Blood · doi:10.1182/blood-2004-02-0405 · Cited by 579
Translocations involving c-myc and c-myc function
Boxer, L. M., & Dang, C. V. (2001) · Oncogene · doi:10.1038/sj.onc.1204595 · Cited by 479
Phosphorylation by Glycogen Synthase Kinase-3 Controls c-Myc Proteolysis and Subnuclear Localization
Gregory, M. A., Qi, Y., & Hann, S. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m310722200 · Cited by 475
Self-citationThe ubiquitin-specific protease USP28 is required for MYC stability
Popov, N., Wanzel, M., Madiredjo, M., Zhang, D., Beijersbergen, R., Bernards, R., Moll, R., Elledge, S. J., & Eilers, M. (2007) · Nature Cell Biology · doi:10.1038/ncb1601 · Cited by 474
Therapeutic targeting of “undruggable” MYC
Llombart, V., & Mansour, M. R. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2021.103756 · Cited by 472
Farrell, A. S., & Sears, R. C. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014365 · Cited by 468
The myc Oncogene: arvelouslomplex
(2002) · Advances in Cancer Research · doi:10.1016/s0065-230x(02)84004-0 · Cited by 463
Skp2 Regulates Myc Protein Stability and Activity
Kim, S. Y., Herbst, A., Tworkowski, K. A., Salghetti, S. E., & Tansey, W. P. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00173-4 · Cited by 440
Molecular Biology of Burkitt’s Lymphoma
Hecht, J. L., & Aster, J. C. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.21.3707 · Cited by 439
An Overview of MYC and Its Interactome
Conacci-Sorrell, M., McFerrin, L., & Eisenman, R. N. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014357 · Cited by 408
The Life Cycle of C-Myc: From Synthesis to Degradation
Sears, R. C. (2004) · Cell Cycle · doi:10.4161/cc.3.9.1145 · Cited by 417
Wei, W., Jin, J., Schlisio, S., Harper, J. W., & Kaelin, W. G. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.005 · Cited by 403
von der Lehr, N., Johansson, S., Wu, S., Bahram, F., Castell, A., Cetinkaya, C., Hydbring, P., Weidung, I., Nakayama, K., Nakayama, K. I., et al. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00193-x · Cited by 408
Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc
Madden, S. K., de Araujo, A. D., Gerhardt, M., Fairlie, D. P., & Mason, J. M. (2021) · Molecular Cancer · doi:10.1186/s12943-020-01291-6 · Cited by 397
Loftus, R. M., Assmann, N., Kedia-Mehta, N., O’Brien, K. L., Garcia, A., Gillespie, C., Hukelmann, J. L., Oefner, P. J., Lamond, A. I., Gardiner, C. M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04719-2 · Cited by 381
Multiple pathways regulated by the tumor suppressor PP2A in transformation
Westermarck, J., & Hahn, W. C. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.02.001 · Cited by 344
SCF ubiquitin ligase-targeted therapies
Skaar, J. R., Pagan, J. K., & Pagano, M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4432 · Cited by 335
Metabolic Codependencies in the Tumor Microenvironment
Dey, P., Kimmelman, A. C., & DePinho, R. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1211 · Cited by 328
Domina, A. M., Vrana, J. A., Gregory, M. A., Hann, S. R., & Craig, R. W. (2004) · Oncogene · doi:10.1038/sj.onc.1207692 · Cited by 327
“Since the degradation of a variety of other PEST proteins is affected by phosphorylation (Rechsteiner, 1990; Clurman et al., 1996; Chen et al., 2000; Gregory and Hann, 2000; Sears et al., 2000; Koepp et al., 2001), we wondered whether this might likewise be the case with MCL1.”
BackgroundMethodSelf-citationBerg, T., Cohen, S. B., Desharnais, J., Sonderegger, C., Maslyar, D. J., Goldberg, J., Boger, D. L., & Vogt, P. K. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.062036999 · Cited by 326
Epstein–Barr virus and Burkitt lymphoma
Brady, G., MacArthur, G. J., & Farrell, P. J. (2008) · Postgraduate Medical Journal · doi:10.1136/jcp.2007.047977 · Cited by 301
Menssen, A., Hydbring, P., Kapelle, K., Vervoorts, J., Diebold, J., Lüscher, B., Larsson, L.-G., & Hermeking, H. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105304109 · Cited by 275
Pianetti, S., Arsura, M., Romieu-Mourez, R., Coffey, R. J., & Sonenshein, G. E. (2001) · Oncogene · doi:10.1038/sj.onc.1204257 · Cited by 265
The Ins and Outs of MYC Regulation by Posttranslational Mechanisms
Vervoorts, J., Lüscher-Firzlaff, J., & Lüscher, B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.r600017200 · Cited by 260
Myc Roles in Hematopoiesis and Leukemia
Delgado, M. D., & Leon, J. (2010) · Genes & Cancer · doi:10.1177/1947601910377495 · Cited by 255
Arnold, H. K., & Sears, R. C. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.7.2832-2844.2006 · Cited by 251
The c‐myc Promoter: Still MysterY and Challenge
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(07)99004-1 · Cited by 211
MYC-Dependent Regulation and Prognostic Role of CIP2A in Gastric Cancer
Khanna, A., Böckelman, C., Hemmes, A., Junttila, M. R., Wiksten, J.-P., Lundin, M., Junnila, S., Murphy, D. J., Evan, G. I., Haglund, C., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp103 · Cited by 185
Carabet, L. A., Rennie, P. S., & Cherkasov, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010120 · Cited by 172
“Myc proteins also contain a central segment rich in proline, glutamic acid, serine, and threonine residues (PEST), which is necessary for rapid Myc degradation but not ubiquitination [39].”
BackgroundChemical and structural studies provide a mechanistic basis for recognition of the MYC G-quadruplex
Calabrese, D. R., Chen, X., Leon, E. C., Gaikwad, S. M., Phyo, Z., Hewitt, W. M., Alden, S., Hilimire, T. A., He, F., Michalowski, A. M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06315-w · Cited by 172
Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma
Gaidano, G. (2003) · Blood · doi:10.1182/blood-2002-11-3606 · Cited by 123
Regulation of apoptosis by the ubiquitin and proteasome pathway
Wójcik, C. (2002) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2002.tb00309.x · Cited by 118
HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications
Harada, T., Ohguchi, H., Grondin, Y., Kikuchi, S., Sagawa, M., Tai, Y.-T., Mazitschek, R., Hideshima, T., & Anderson, K. C. (2017) · Leukemia · doi:10.1038/leu.2017.144 · Cited by 89
Liso, A. (2006) · Blood · doi:10.1182/blood-2005-10-3949 · Cited by 84
Bouhaddou, M., Barrette, A. M., Stern, A. D., Koch, R. J., DiStefano, M. S., Riesel, E. A., Santos, L. C., Tan, A. L., Mertz, A. E., & Birtwistle, M. R. (2018) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1005985 · Cited by 58
Max deletion destabilizes MYC protein and abrogates Eµ- Myc lymphomagenesis
Mathsyaraja, H., Freie, B., Cheng, P.-F., Babaeva, E., Catchpole, J. T., Janssens, D., Henikoff, S., & Eisenman, R. N. (2019) · Genes & Development · doi:10.1101/gad.325878.119 · Cited by 54
Liu, L., & Eisenman, R. N. (2012) · Genes & Cancer · doi:10.1177/1947601912448067 · Cited by 47
“Phosphorylation of serine 62 (S62) leads to increased Myc stabilization but also acts as to prime phosphorylation, permitting glycogen synthase kinase 3β (GSK3β) to phosphorylate threonine 58 (T58), which in turn leads to Myc degradation.(17,19-21) The GSK3βmediated phosphorylation of c-Myc at T58 in MBI provides a di…”
BackgroundcMyc increases cell number through uncoupling of cell division from cell size in CHO cells
Kuystermans, D., & Al-Rubeai, M. (2009) · BMC Biotechnology · doi:10.1186/1472-6750-9-76 · Cited by 33
The fine-tuning of proteolytic pathways in Alzheimer’s disease
Cecarini, V., Bonfili, L., Cuccioloni, M., Mozzicafreddo, M., Angeletti, M., Keller, J. N., & Eleuteri, A. M. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2238-6 · Cited by 21
Janghorban, M., Langer, E. M., Wang, X., Zachman, D., Daniel, C. J., Hooper, J., Fleming, W. H., Agarwal, A., & Sears, R. C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188910 · Cited by 19
Metadata
- Authors
- Gregory, M. A., & Hann, S. R.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2000-04
- Volume
- 20
- Issue
- 7
- Pages
- 2423-2435
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2164461769
- Cited by
- 469
- References
- 73
- FWCI
- 6.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.